Mineralys Therapeutics (MLYS) Net Cash Flow (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Net Cash Flow of -$60.1 million for Q1 2026, down 34.53% sequentially from -$44.7 million in Q4 2025, and down 218.12% YoY from $50.9 million in Q1 2025.
Mineralys Therapeutics (MLYS) Net Cash Flow (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at -$60.1 million in Q1 2026.
- Quarterly Net Cash Flow fell 218.12% year-over-year to -$60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.2 million (down 170.02% YoY) and the FY2025 annual result came in at $58.8 million, down 9.19% from the prior year.
- Net Cash Flow eased to -$60.1 million in Q1 2026 per MLYS's latest filing, from -$44.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $115.9 million in Q3 2025 and troughed at -$79.3 million in Q3 2022.
- A 5-year average of $6.0 million and a median of $5.4 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 832.74% in 2023, then plunged 365.83% in 2025.
- Over 5 years, Net Cash Flow stood at $38.7 million in 2022, then sank by 195.48% to -$37.0 million in 2023, then surged by 145.46% to $16.8 million in 2024, then slumped by 365.83% to -$44.7 million in 2025, then plunged by 34.53% to -$60.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$60.1 million, -$44.7 million, and $115.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 25.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.52 Mn |
| Jun 30, 2026 | 25.52 Mn |
| Mar 31, 2026 | -60.14 Mn |
| Mar 31, 2026 | -60.14 Mn |
| Dec 31, 2025 | -44.70 Mn |
| Dec 31, 2025 | -44.70 Mn |
| Sep 30, 2025 | 115.88 Mn |
| Sep 30, 2025 | 115.88 Mn |
| Jun 30, 2025 | -63.26 Mn |
| Jun 30, 2025 | -63.26 Mn |
| Mar 31, 2025 | 50.92 Mn |
| Mar 31, 2025 | 50.92 Mn |
| Dec 31, 2024 | 16.82 Mn |
| Dec 31, 2024 | 16.82 Mn |
| Sep 30, 2024 | 29.42 Mn |
| Sep 30, 2024 | 29.42 Mn |
| Jun 30, 2024 | -22.56 Mn |
| Jun 30, 2024 | -22.56 Mn |
| Mar 31, 2024 | 41.11 Mn |
| Mar 31, 2024 | 41.11 Mn |